Wilson Disease — Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
Citation(s)
A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 36 Months